Home » Stocks » SLNO

Soleno Therapeutics, Inc. (SLNO)

Stock Price: $1.61 USD -0.01 (-0.62%)
Updated Oct 29, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 128.15M
Revenue (ttm) n/a
Net Income (ttm) -26.98M
Shares Out 79.59M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 29, 2020
Last Price $1.61
Previous Close $1.62
Change ($) -0.01
Change (%) -0.62%
Day's Open 1.65
Day's Range 1.56 - 1.67
Day's Volume 274,023
52-Week Range 1.30 - 4.39

More Stats

Market Cap 128.15M
Enterprise Value 65.94M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 79.59M
Float 53.72M
EPS (basic) -0.65
EPS (diluted) -0.66
FCF / Share -0.48
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.61M
Short Ratio 1.54
Short % of Float 3.00%
Beta 0.44
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.64
Revenue n/a
Operating Income -30.03M
Net Income -26.98M
Free Cash Flow -21.99M
Net Cash 62.20M
Net Cash / Share 0.78
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -33.23%
ROE -77.06%
ROIC 541.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.33*
(417.39% upside)
Low
8.00
Current: $1.61
High
9.00
Target: 8.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue----0.61-3.00
Gross Profit----0.25-3.00
Operating Income-23.20-13.73-9.87-8.32-12.16-5.16-0.85
Net Income-30.77-13.34-15.39-12.07-15.91-13.24-3.71
Shares Outstanding34.1420.988.983.101.890.250.11
Earnings Per Share-0.90-0.64-1.71-5.07-8.45-52.10-34.60
Operating Cash Flow-17.38-11.68-9.95-13.50-10.30-4.48-0.89
Capital Expenditures-0.02-0.01--0.01-0.06-0.03-
Free Cash Flow-17.40-11.69-9.95-13.51-10.36-4.52-0.89
Cash & Equivalents20.7324.0817.142.765.537.981.29
Total Debt0.31----0.1013.99
Net Cash / Debt20.4324.0817.142.765.537.88-12.70
Assets38.1743.1539.025.568.208.401.59
Liabilities23.2312.7412.212.134.9819.5939.45
Book Value14.9530.4126.823.443.22-11.19-37.86
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Soleno Therapeutics, Inc.
Country United States
Employees 10
CEO Anish Bhatnagar

Stock Information

Ticker Symbol SLNO
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: SLNO
IPO Date November 13, 2014

Description

Soleno Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.